July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Interleukin-8 production by cells in peripheral blood is associated with age-related macular degeneration lesion activity during anti-VEGF treatment and with variants of the interleukin-8 gene
Author Affiliations & Notes
  • Ilkka J Immonen
    Ophthalmology, Helsinki University Hospital, Helsinki, Finland
  • Alexandra Robciuc
    Ophthalmology, Helsinki University Hospital, Helsinki, Finland
  • Jarno Kivioja
    Dept. of Medical Genetics, University of Helsinki, Finland
  • Jukka Moilanen
    Ophthalmology, Helsinki University Hospital, Helsinki, Finland
  • Sanna Seitsonen
    Ophthalmology, Helsinki University Hospital, Helsinki, Finland
  • Irma Järvelä
    Dept. of Medical Genetics, University of Helsinki, Finland
  • Asta Hautamäki
    Ophthalmology, Helsinki University Hospital, Helsinki, Finland
  • Footnotes
    Commercial Relationships   Ilkka Immonen, None; Alexandra Robciuc, None; Jarno Kivioja, None; Jukka Moilanen, None; Sanna Seitsonen, None; Irma Järvelä, None; Asta Hautamäki, None
  • Footnotes
    Support  The Finnish Cultural Foundation, Helsinki, Finland, The Eye Foundation, Helsinki, Finland, The Eye and Tissue Bank Foundation, Helsinki, Finland, Mary and Georg C. Ehrnrooth Foundation, Helsinki, Finland, and The Finnish Ophthalmological Society, Oulu, Finland
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 115. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ilkka J Immonen, Alexandra Robciuc, Jarno Kivioja, Jukka Moilanen, Sanna Seitsonen, Irma Järvelä, Asta Hautamäki; Interleukin-8 production by cells in peripheral blood is associated with age-related macular degeneration lesion activity during anti-VEGF treatment and with variants of the interleukin-8 gene. Invest. Ophthalmol. Vis. Sci. 2019;60(9):115.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We have previously found an interleukin-8 (IL-8) polymorphism (SNP) at rs4073 to modulate anti-VEGF treatment response and the age of onset of patients with exudative age-related macular degeneration (eAMD). Here, we study IL-8 production by cells in peripheral blood for associations with variants of IL-8 gene polymorphisms and anti-VEGF treatment response in patients with exudative age-related macular degeneration (eAMD).

Methods : Unstimulated and bacterial lipopolysaccharide (LPS)-stimulated IL-8 production by cells in blood samples of 80 eAMD patients were analyzed. Forty of these were receiving active treatment, and were evaluated for treatment response at the time of sampling. All patients were genotyped for rs4073. Samples of 57 of these and of 52 additional patients were also analyzed for rs2227306 another IL-8 gene SNP site, reported to be associated with a higher production of IL-8.

Results : Higher stimulated IL-8 production was associated with older age (P = 0.003, Generalized estimating equations) and the presence of intra- or subretinal fluid in OCTs during treatment compared with no treatment (P = 0.046). Lower production with acetylsalicylic acid use (P = 0.028). In samples taken during anti-VEGF therapy, lower IL-( production was was found in females (P = 0.018), with daily use of any non-steroidal anti-inflammatory agents (P = 0.012) and the TT genotype of rs4073 (P = 0.007).
A strong linkage disequilibrium existed between the rs4073 and rs2227306, both associating equally with the studied variables.

Conclusions : High IL-8 production by blood cells seems to be associated with the presence of fluid in OCTs during anti-VEGF treatment and with the genotype of rs4073 showing strong linkage disequilibrium with the rs2227306.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×